Literature DB >> 27626506

Fusion imaging of contrast-enhanced ultrasound and contrast-enhanced CT or MRI before radiofrequency ablation for liver cancers.

Xiao-Wan Bo1, Hui-Xiong Xu1, Dan Wang1, Le-Hang Guo1, Li-Ping Sun1, Xiao-Long Li1, Chong-Ke Zhao1, Ya-Ping He1, Bo-Ji Liu1, Dan-Dan Li1, Kun Zhang1.   

Abstract

OBJECTIVE: To investigate the usefulness of fusion imaging of contrast-enhanced ultrasound (CEUS) and CECT/CEMRI before percutaneous ultrasound-guided radiofrequency ablation (RFA) for liver cancers.
METHODS: 45 consecutive patients with 70 liver lesions were included between March 2013 and October 2015, and all the lesions were identified on CEMRI/CECT prior to inclusion in the study. Planning ultrasound for percutaneous RFA was performed using conventional ultrasound, ultrasound-CECT/CEMRI and CEUS and CECT/CEMRI fusion imaging during the same session. The numbers of the conspicuous lesions on ultrasound and fusion imaging were recorded. RFA was performed according to the results of fusion imaging. Complete response (CR) rate was calculated and the complications were recorded.
RESULTS: On conventional ultrasound, 25 (35.7%) of the 70 lesions were conspicuous, whereas 45 (64.3%) were inconspicuous. Ultrasound-CECT/CEMRI fusion imaging detected additional 24 lesions thus increased the number of the conspicuous lesions to 49 (70.0%) (70.0% vs 35.7%; p < 0.001 in comparison with conventional ultrasound). With the use of CEUS and CECT/CEMRI fusion imaging, the number of the conspicuous lesions further increased to 67 (95.7%, 67/70) (95.7% vs 70.0%, 95.7% vs 35.7%; both p < 0.001 in comparison with ultrasound and ultrasound-CECT/CEMRI fusion imaging, respectively). With the assistance of CEUS and CECT/CEMRI fusion imaging, the confidence level of the operator for performing RFA improved significantly with regard to visualization of the target lesions (p = 0.001). The CR rate for RFA was 97.0% (64/66) in accordance to the CECT/CEMRI results 1 month later. No procedure-related deaths and major complications occurred during and after RFA.
CONCLUSION: Fusion of CEUS and CECT/CEMRI improves the visualization of those inconspicuous lesions on conventional ultrasound. It also facilitates improvement in the RFA operators' confidence and CR of RFA. Advances in knowledge: CEUS and CECT/CEMRI fusion imaging is better than both conventional ultrasound and ultrasound-CECT/CEMRI fusion imaging for lesion visualization and improves the operator confidence, thus it should be recommended to be used as a routine in ultrasound-guided percutaneous RFA procedures for liver cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27626506      PMCID: PMC5124839          DOI: 10.1259/bjr.20160379

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  42 in total

Review 1.  Hepatocellular carcinoma: current management.

Authors:  Charles H Cha; M Wasif Saif; Brett H Yamane; Sharon M Weber
Journal:  Curr Probl Surg       Date:  2010-01       Impact factor: 1.909

2.  Comparison of the effectiveness and safety of ultrasound- and CT-guided percutaneous radiofrequency ablation of non-operation hepatocellular carcinoma.

Authors:  Jing Wu; Ping Chen; Yang-gui Xie; Nian-mei Gong; Lin-lin Sun; Chun-feng Sun
Journal:  Pathol Oncol Res       Date:  2014-12-03       Impact factor: 3.201

3.  Magnetic navigation in ultrasound-guided interventional radiology procedures.

Authors:  H-X Xu; M-D Lu; L-N Liu; L-H Guo
Journal:  Clin Radiol       Date:  2011-12-06       Impact factor: 2.350

4.  Diagnostic value of contrast-enhanced ultrasound, computed tomography and magnetic resonance imaging for focal liver lesions: a meta-analysis.

Authors:  Limei Xie; Yang Guang; Hailong Ding; Ailu Cai; Ying Huang
Journal:  Ultrasound Med Biol       Date:  2011-04-30       Impact factor: 2.998

5.  Clinical evaluation of spatial accuracy of a fusion imaging technique combining previously acquired computed tomography and real-time ultrasound for imaging of liver metastases.

Authors:  Antoine Hakime; Frederic Deschamps; Enio Garcia Marques De Carvalho; Christophe Teriitehau; Anne Auperin; Thierry De Baere
Journal:  Cardiovasc Intervent Radiol       Date:  2010-09-16       Impact factor: 2.740

Review 6.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

7.  Radiofrequency ablation of hepatocellular carcinoma: value of virtual CT sonography with magnetic navigation.

Authors:  Yasunori Minami; Hobyung Chung; Masatoshi Kudo; Satoshi Kitai; Shunsuke Takahashi; Tatsuo Inoue; Kuzuomi Ueshima; Hitoshi Shiozaki
Journal:  AJR Am J Roentgenol       Date:  2008-06       Impact factor: 3.959

8.  Total-liver-volume perfusion CT using 3-D image fusion to improve detection and characterization of liver metastases.

Authors:  Martijn R Meijerink; Jan Hein T M van Waesberghe; Lineke van der Weide; Petrousjka van den Tol; Sybren Meijer; Cornelis van Kuijk
Journal:  Eur Radiol       Date:  2008-05-20       Impact factor: 5.315

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

10.  Hepatocellular carcinoma: natural history, current management, and emerging tools.

Authors:  Christopher L Tinkle; Daphne Haas-Kogan
Journal:  Biologics       Date:  2012-07-17
View more
  12 in total

Review 1.  Thermal Ablation of Metastatic Colon Cancer to the Liver.

Authors:  Juan C Camacho; Elena N Petre; Constantinos T Sofocleous
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

2.  Comparative study of conventional US, contrast enhanced US and enhanced MR for the follow-up of prostatic radiofrequency ablation.

Authors:  Chao Feng; Bin Hu; Bing Hu; Lei Chen; Jia Li; Jin Huang
Journal:  Exp Ther Med       Date:  2017-04-28       Impact factor: 2.447

Review 3.  Ultrasound fusion imaging technologies for guidance in ablation therapy for liver cancer.

Authors:  Yasunori Minami; Masatoshi Kudo
Journal:  J Med Ultrason (2001)       Date:  2020-02-08       Impact factor: 1.314

4.  Magnetic resonance and ultrasound image-guided navigation system using a needle manipulator.

Authors:  Atsushi Yamada; Junichi Tokuda; Shigeyuki Naka; Koichiro Murakami; Tohru Tani; Shigehiro Morikawa
Journal:  Med Phys       Date:  2019-12-29       Impact factor: 4.071

Review 5.  Design and Challenges of Sonodynamic Therapy System for Cancer Theranostics: From Equipment to Sensitizers.

Authors:  Zhuoran Gong; Zhifei Dai
Journal:  Adv Sci (Weinh)       Date:  2021-03-12       Impact factor: 16.806

6.  Percutaneous radiofrequency ablation for hepatic metastasis of colorectal cancer: assessment of tumor visibility and the feasibility of the procedure with planning ultrasonography.

Authors:  Jeong Woo Bae; Min Woo Lee; Tae Wook Kang; Kyoung Doo Song; Dong Ik Cha; Ji Hye Min; Hyunchul Rhim
Journal:  Ultrasonography       Date:  2021-06-22

7.  Contrast enhancement for ultrasound-guided interventions: when to use it and what to expect?

Authors:  Zeno Sparchez; Tudor Mocan; Rares Craciun; Mihaela Sparchez; Christian Nolsøe
Journal:  Ultrasonography       Date:  2021-12-09

8.  Percutaneous Radiofrequency Ablation of Small (1-2 cm) Hepatocellular Carcinomas Inconspicuous on B-Mode Ultrasonographic Imaging: Usefulness of Combined Fusion Imaging with MRI and Contrast-Enhanced Ultrasonography.

Authors:  Min Woo Lee; Hyo Keun Lim; Hyunchul Rhim; Dong Ik Cha; Tae Wook Kang; Kyoung Doo Song; Ji Hye Min; Geum-Youn Gwak; Seonwoo Kim; David S K Lu
Journal:  Can J Gastroenterol Hepatol       Date:  2018-06-14

Review 9.  Role of Fusion Imaging in Image-Guided Thermal Ablations.

Authors:  Serena Carriero; Gianmarco Della Pepa; Lorenzo Monfardini; Renato Vitale; Duccio Rossi; Andrea Masperi; Giovanni Mauri
Journal:  Diagnostics (Basel)       Date:  2021-03-19

10.  Contrast-enhanced ultrasonography for the evaluation of malignant focal liver lesions.

Authors:  Maria Cristina Chammas; André Leopoldino Bordini
Journal:  Ultrasonography       Date:  2021-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.